Spark Therapeutics’ promising gene therapy for vision loss could cost $1 million – MarketWatch
MarketWatch |
Spark Therapeutics' promising gene therapy for vision loss could cost $1 million
MarketWatch Spark Therapeutics' gene therapy for an otherwise incurable rare eye disease, if approved, could be a major milestone for the disease itself as well as the field of gene therapy. The therapy, Luxturna, was recommended for approval by a Food and Drug … Spark Therapeutics Inc. (ONCE) Moves Lower on Volume Spike for October 13 Spark Therapeutics (NASDAQ:ONCE): BMO Capital Reconfirms “Outperform” Rating Today, Has a Target of $101/Share 19.91 % to Target, BMO Capital Reconfirms 'Outperform' Rating on Spark Therapeutics (NASDAQ:ONCE) Shares Today |
